FDA Approves New Treatment for Myasthenia Gravis
/PRNewswire/ -- The U.S. Food and Drug Administration today approved Vyvgart (efgartigimod) for the treatment of generalized myasthenia gravis (gMG) in adults...
Stay updated with breaking news from Billy Dunn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The U.S. Food and Drug Administration today approved Vyvgart (efgartigimod) for the treatment of generalized myasthenia gravis (gMG) in adults...
Dundonians rallying to support local boy Bobby McGuinnis after he was diagnosed with leukaemia are set to host a Halloween fundraiser.
An East Texas family is growing restless as they wait for Dallas Police to find the driver who hit Billy Dunn while on a motorcycle and left him for dead.
How an Unproven Alzheimerâs Drug Got Approved Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogenâs Aduhelm, or aducanumab. The F.D.A. conducted an internal inquiry this year after allegations were made that the agency was collaborating too closely with Biogen, maker of the Alzheimerâs drug Aduhelm.Credit...Andrew Kelly/Reuters Published July 19, 2021Updated July 20, 2021, 9:29 a.m. ET Two months before the Food and Drug Administrationâs deadline to decide whether to approve Biogenâ...
Print this article Janet Woodcock, acting head of the Food and Drug Administration, has endured mounting criticism for her role as overseer in the agency’s decision to approve a controversial Alzheimer’s treatment despite dubious scientific backing, with some consumer advocates saying she should be skipped for the permanent post. “I think it certainly endangers her potential nomination … and now, we think she should be removed from her acting position because of the decision to approve [the Alzheimer’s treatment] aducanumab,” said Michael Carome, director of health research at t...